SNPMiner Trials: Clinical Trial Report
Report for Clinical Trial NCT00586651
Developed by Shray Alag, 2019.
SNP Clinical Trial Gene
This is an 18-week open-label, multicenter study to evaluate the efficacy and tolerability of
CEP-701 (lestaurtinib) treatment in patients with Polycythemia Vera (PV) and patients with
Essential Thrombocytosis (ET).
Name: lestaurtinib
Description: 60 mg bid - 120 mg bid for an 18 weeks (126 days) treatment durationType: Drug
lestaurtinib
Primary Outcomes
Measure: Determine whether a specific reduction in the JAK2 V617F allele has been indicated in this study.
Time: 18 weeks +
Secondary Outcomes
Measure: - improvements in hemoglobin values, neutrophil count, and platelet count. - reduction in dose of hydroxyurea - reduction in splenic enlargement - rate of phlebotomy
Time: 18 weeks +
Purpose: Treatment
Single Group Assignment
There is one SNP
SNPs
1 V617F
An Open-Label Study of Oral CEP-701 in Patients With Polycythemia Vera or Essential Thrombocytosis With the JAK2 V617F Mutation. --- V617F ---
Determine whether a specific reduction in the JAK2 V617F allele has been indicated in this study.. null. --- V617F ---
- The patient has a detectable JAK2 V617F mutation. --- V617F ---
HPO Nodes
HPO:Polycythemia
Genes 15
PKLR SH2B3 VHL JAK2 ENG EPO EPOR SLC30A10 EPAS1 EGLN1 BPGM ACVRL1 CYB5R3 FH GATA1 hr>Thrombocytosis
Genes 25
MPL IFNGR1 CD55 JAK2 TET2 ELANE RPS19 RPSA HMGCL TMEM173 ABL1 THPO RUNX1 ZMPSTE24 LMNA SH2B3 HBB BCR ACAT1 ADA2 MTHFD1 CALR TTC37 TBC1D24 PMM2 hr>